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2Abstract
Purpose: To report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional 
immunosuppressants, with subsequent remission following treatment with alemtuzumab.
Methods: Case report. Patient was treated with alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal 
antibody that has recently been approved for use in relapsing MS.
Results: A 17-year old female presented with bilateral optic neuritis and subsequently bilateral intermediate 
uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received 
treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional 
immunosuppressants responded to alemtuzumab, inducing remission.
Conclusions: To our knowledge this is the first such report of alemtuzumab treatment in MS-associated ocular 
inflammatory disease and may demonstrate a potential utility for this drug in related conditions.
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3Introduction
Alemtuzumab is an anti-CD52 monoclonal antibody recently approved for use in relapsing multiple sclerosis 
(MS). It has been shown to be highly effective at reducing clinical relapse rates and in some studies slowing, or 
even reversing, disability outcomes.
1-3
 CD52 is present on approximately 5% of the cell surface of lymphocytes 
and is also expressed, albeit at lower levels, on monocytes, macrophages, eosinophils and NK cells.
4, 5
Treatment 
with alemtuzumab results in a rapid depletion of circulating lymphocytes with subsequent beneficial 
reconstitution.
6
Optic neuritis is the most commonly associated ocular manifestation of MS, however intraocular inflammation is 
reported to occur in 0.4% to 26.9% of patients.
7
Intermediate uveitis is the most common type but all anatomic 
sub-types of uveitis have been reported.
7, 8
Secondary complications including cystoid macular oedema can also
occur; at which point the disease is difficult to manage and may be refractory to standard immunosuppressive 
treatments.
7, 8
Although the exact prevalence of macular oedema in MS-associated uveitis is unknown, it is 
estimated to affect 37% of patients with MS-associated intermediate uveitis.
8
Alemtuzumab has previously been 
shown to be beneficial in ocular inflammatory disease initially in a single case refractory to treatment and 
complicated by standard therapeutic side effects, then a case series of 10 patients with systemic autoimmune 
disease and associated ocular inflammatory disease and finally in 18 patients with Behçet’s disease.
9-11
Although the association between MS and uveitis is well established, the effect of alemtuzumab on MS-associated 
intraocular inflammation is unknown. We present a patient with MS and alemtuzumab-induced remission of 
uveitis.
4Case report
A 17-year-old female presented with an episode of optic neuritis (ON) affecting the right eye, followed by ON of 
the left eye 10 months later. One month after this she was diagnosed with bilateral intermediate uveitis with 
peripheral retinal vasculitis and associated macular oedema (figure 1). Routine uveitis screening was performed to 
exclude common systemic associations. Syphilis serology, antinuclear and antinuclear cytoplasmic antibodies and 
QuantiFERON® Gold tests were negative, and a chest X-ray was unremarkable. Following initial screening she 
was referred for a neurological opinion. Subsequent cranial magnetic resonance imaging (MRI) was normal with 
an unremarkable cerebrospinal fluid examination other than positive CSF oligoclonal bands unpaired in a serum 
sample. For her ophthalmological symptoms the patient commenced immunomodulatory treatment with a 
combination of oral prednisolone and cyclosporine, which was then switched to tacrolimus.
Three years after initial presentation the patient experienced transient limb sensory symptoms with a repeat cranial 
MRI scan demonstrating a single, left sided deep white matter lesion as well as non-specific abnormal cord signal 
at C6. In the following 3 years the patient experienced a further 5 episodes of transient neurological dysfunction
including 4 in one 12-month period. A further MRI demonstrated new lesions in the medulla, cerebellum, anterior 
pons and in the left periventricular region and a diagnosis of relapsing-MS was made. Of note, high resolution 
computerised tomography of the thorax and anti-aquaporin-4 antibodies were negative.
As a result of highly active disease, alemtuzumab was commenced with a 5-day treatment of 12mg/day with a
routine, second, 3-day course of alemtuzumab 12 months later. Following a further clinical relapse 3 years after 
treatment initiation and repeat imaging demonstrating new and enhancing lesions the patient received a 3
rd
, 3-day 
course of alemtuzumab.
Ophthalmological management has proved difficult throughout with the patient requiring regular courses of oral 
steroids and been intolerant/failed treatment with cyclosporine, tacrolimus and mycophenolate mofetil after. In 
particular, the left eye required periocular and intraocular steroids (Figure 2). After the first course of 
alemtuzumab, macular oedema was present in the left eye despite two orbital floor injections of triamcinolone for 
approximately 6 months after infusion. Following this, visual acuity and central macular thickness remained 
stable until the second course of alemtuzumab. Following the second treatment, the patient experienced a flare in 
symptoms lasting approximately 3 months. However, stabilisation of disease was again observed for a period of 9 
months. Macular oedema subsequently worsened, was difficult to control and required an intraocular 
dexamethasone implant in order to control the inflammation in the left eye.  Following this she received the 3
rd
course of alemtuzumab and despite the effect of intraocular dexamethasone wearing off she has remained well 
controlled for the last 12 months not even requiring oral steroids. Recent ophthalmological review has 
demonstrated stable vision with OCT showing a healthy macular in the right eye and minute cysts in the left eye. 
Of note, the patient has developed Graves’ disease with associated thyroid eye disease following the second 
course of alemtuzumab; a well described autoimmune side effect of the drug.
5Figure Captions:
Fig 1 Fluorescein angiography (FA) and optical coherence tomography (OCT) at presentation. Top figures show 
FA for the right and left eye with peripheral vascular leakage, macular leakage and hyperfluorescent optic disc in 
both eyes. Inferior figures show the OCT at the level of the fovea disclosing bilateral macular oedema. A and C 
corresponds to images of the right eye and B and D to the left eye.
Fig 2 Visual acuity (VA) and central macular thickness (CMT) diagrams, showing the evolution of both 
parameters during the follow-up. Arrows sign the changes on treatment according to the superior legend. Vertical 
lines in the graphs represent a time interval of approximately 6 months. RE: right eye; LE: left eye; VA: visual 
acuity; CMT: central macular thickness.
6Discussion
We present a case of MS-associated uveitis refractory to conventional immunomodulatory therapy with 
subsequent remission achieved following alemtuzumab treatment. Alemtuzumab has previously been used for 
treating intraocular inflammation, albeit with scarce case series and case reports in the literature but with 
promising results.
9-11
In contrast to previously reported cases in which patients received 1 cycle of treatment, our 
patient received 3 cycles of treatment. In our patient the macular oedema resolved and improvement was 
maintained for approximately 6 months after the addition of alemtuzumab without other significant changes on 
the systemic or local treatment after the first and the second infusion of alemtuzumab. Similarly in a case report 
using alemtuzumab for undifferentiated unilateral panuveitis, the patient experienced 2 flare-ups of intraocular 
inflammation during the 4 months after treatment with posterior induced remission, which coincides with the 
response in our patient.
10
Uveitis is traditionally considered an autoimmune disease initiated by loss of immune tolerance to retinal proteins 
and tyrosinase-related products, orchestrated by two subsets of CD4+ T cells: Th1 and Th17 cells.
12
The 
mechanism of action of alemtuzumab helps to explain its potential effect on uveitis. Following treatment with 
alemtuzumab there is a rapid and profound reduction in lymphocytes with recovery varying by cell type. B 
lymphocytes recover the quickest, followed by CD8+ and CD4+ T lymphocytes.
13-15
The population of 
lymphocytes is altered following treatment, with regulatory T cells (Tregs) dominating the milieu, which is 
thought to be beneficial.
16-18
This time to repopulation with Tregs may explain the delayed effect seen on ocular 
disease in our case.
The main side effects of alemtuzumab are well established and relate to acquired autoimmune diseases, with a 
particular predilection for the thyroid gland.
19
Although serious, these side effects are predictable and can be 
anticipated with an active surveillance program. Despite these side effects, this case demonstrates the potential 
utility of alemtuzumab for treatment of MS-associated uveitis, which was more efficacious than all other standard 
immunomodulatory treatment used. Patients with concomitant MS and uveitis may therefore expect improvement
in ocular symptoms following treatment with alemtuzumab.
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